Lipid nanoparticles for bone marrow-targeted RNA therapeutics

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Hematology

Background:

• Lipid nanoparticles (LNPs) are crucial for RNA delivery, particularly for bone marrow (BM) applications like leukemia treatment and regenerative therapies.
• Current LNP formulations show limited accumulation in the BM after systemic administration due to physiological barriers.
• These barriers include rapid clearance, liver sequestration, complement activation, and poor endosomal escape, hindering extrahepatic therapeutic efficacy.

Purpose of the Study:

• To review the challenges and strategies for enhancing LNP delivery to the bone marrow.
• To characterize BM physiology and its barriers to LNP accumulation.
• To highlight innovative LNP designs and targeting approaches for improved BM-specific RNA therapeutics.

Main Methods:

• Literature review of LNP delivery to the bone marrow.
• Analysis of BM physiology and barriers to nanoparticle accumulation.
• Evaluation of passive and active targeting strategies for LNPs.
• Assessment of preclinical in vitro models and LNP design innovations.

Main Results:

• Bone marrow delivery of therapeutic RNA via LNPs faces significant obstacles.
• Physiological barriers like mononuclear phagocyte system clearance and liver sequestration limit LNP BM accumulation.
• Innovative strategies in LNP design, stability, circulation time, and targeting are emerging.

Conclusions:

• Overcoming BM delivery barriers is essential for realizing the potential of LNP-based RNA therapeutics.
• Next-generation LNPs require enhanced stability, circulation, and targeted delivery for BM-associated diseases.
• Advances in LNP design and understanding of BM physiology pave the way for novel treatments.